Clinical Trial Update: HIV Risk Reduction in Subutex Injectors in Tbilisi [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update assessing HIV risk reduction among individuals injecting Subutex (buprenorphine) in Tbilisi has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Subutex (buprenorphine)

Snippet

Sponsor: University of Pennsylvania | Conditions: HIV | Phase 3 | Status: COMPLETED